Table 4.
Uptake of risk-reducing bilateral salpingo-oophorectomy by variant status separately for women with a strong and no/minimal family history
| Variant status | Number of women who had RRBSO within 12 months since enrolment (N = 127)a | Number of women who have not had a RRBSO within 12 months but reported intention to undergo RRBSO (N = 90)b | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Family history | No family history | Total | Family historyd | No family history | Total | |||||||
| Tot. N | N (%) | Tot. N | N (%) | Tot. N | N (%) | Tot. N | N (%) | Tot. N | N (%) | Tot. N | N (%) | |
| Variant carriers | 9 | 5 (55.6) | 9 | 0 (0.0) | 18 | 5 (27.8) | 3 | 3 (100.0) | 9 | 8 (88.9) | 12 | 11 (91.7) |
| No variant found | 64 | 9 (14.1) | 45 | 3 (6.7)c | 109 | 12 (10.9) | 44 | 7 (15.9) | 34 | 4 (11.8) | 78 | 11 (14.1) |
| Total | 73 | 14 (19.2) | 54 | 3 (5.6) | 127 | 17 (13.4) | 47 | 10 (21.3) | 43 | 12 (27.9) | 90 | 22 (24.4) |
Tot. N Total N separately for women with a strong family history and no/minimal family history, Variant carrier carrier of a BRCA1 or BRCA2 pathogenic variant, RRBSO risk-reducing bilateral salpingo-oophorectomy
a The missing data for one woman. Self-reported as at 12-months post-enrolment questionnaire and as per medical records for women with missing self-report data
b The data on intention to undergo RRBSO are missing for 20 women
c Of the three FH− non-carriers who had an RRBSO, all had oestrogen receptor positive tumours